Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Kos Pharmaceuticals, Inc (KOSP) -- Ignore unavailable to you. Want to Upgrade?

To: mopgcw who wrote (100)	11/4/2004 1:02:17 AM
From: Lance Bredvold	Read Replies (1) \| Respond to of 118

URL for the earnings release. Apparently SI won't accept the misspellings in the URL and I don't know how to work around that yet. Maybe if I skip the preview: phx.corporate-ir.net It was very brave of the GS analyst to publish his quess so late before earnings. And would have been pretty stupid if anyone important would remember what he said. He was not that far off on Advicor sales which turned out to be $27.9mm. But missed Azmacort by a huge amount since revenues came in at $21.6mm. Then we have the annual earnings prediction he made of something like $1.70. Management had actually predicted over 100% earnings growth (to at least $3.06) sometime in the last quarter and today restated the 100% growth prediction. Wasn't he paying attention? Apparently his script sources for Azmacort are not very reliable. The company stated that their relaunch of the product occurred on August 1 and that their 50 (so far 47) man sales force had managed to turn around the decline in unpromoted prescriptions and actually grow them in both August and Sept. It almost sounded like they were purposefully targeting that response to the GS mistake. I enjoy listening to the KOS conference calls. At least while they have such excellent results to report. Clearly a sales driven organization which clearly and emphatically points out there own strengths. Sort of like Apache Oil, it's fun to watch a well organized team take discarded or underappreciated products and turn them into viable competitors to the major pharma's strategic offerings. Listen to the conference call. Someone estimated the history of extensions to the Barr Labs suit which I'd not heard summarized before. Everyone was very careful to point out that delaying the court case was not part of any strategy they engaged in, but the net effect of new patents was that KOS was able to enjoy more time to broaden its product stream. I also enjoyed hearing a description of what is happening with Niaspan low flush. It was pointed out that less flushing has been the goal from the beginning and that the current Niaspan is already a significant improvement from other formulations of niacin. I believe he said 35% of users never experience flushing and among the rest, they experience flushing from three to 6 times in a 6 month period. The talk sort of made me feel like low flush was an incremental and not real significant improvement. The Simvastatin/niaspan combo sounded more significant. And they sounded excited by the presentation coming from DR. Taylor I believe of results from the Arbiter II trial. I imagine everyone here has read the Pharmaceutical Executive Magazine cover story on KOS by now. It you haven't it gives a nice history of the company and its founders and is brought to one's attention during the CC. I found it through a post on the Yahoo board which is probably the highest recommended post over the last week. Of, course, from the looks of things, a post here is pretty much talking to oneself. And that is OK with me. Best regards, Lance